Panel Discussion: Defining the Therapeutic Windows of Drugs to Ensure Patient Safety Whilst Maintaining Drug Efficacy

Time: 9:50 am
day: Day One


  • Balancing the therapeutic index versus safety in targeting complement
  • Discussing this in the context of disease versus healthy complement inhibition
  • Reviewing the therapeutic window when you target classical, lectin or alternative pathways
  • Discussing pharmacokinetics of targeting complement
  • Specifying inclusion/exclusion criteria put in place specifically due to safety considerations e.g. avoiding comorbidities or infections